<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Immunity &amp; Ageing - Latest articles</title>
		<link>http://www.immunityageing.com</link>
		<description>The latest articles from Immunity &amp; Ageing (ISSN 1742-4933) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/5/1/5"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/5/1/4"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/5/1/3"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/5/1/2"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/5/1/1"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/4/1/9"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/4/1/8"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/4/1/7"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/4/1/6"/>			    
            
				    <rdf:li rdf:resource="http://www.immunityageing.com/content/4/1/5"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.immunityageing.com/content/5/1/5">
            
            <title>Cell autonomous expression of inflammatory genes 
in biologically aged fibroblasts associated with 
elevated NF-kappaB activity
</title>
			<description>Background:
Chronic inflammation is a well-known corollary of the aging process and is believed to significantly contribute to morbidity and mortality of many age-associated chronic diseases. However, the mechanisms that cause age-associated inflammatory changes are not well understood. Particularly, the contribution of cell stress responses to age-associated inflammation in 'non-inflammatory' cells remains poorly defined. The present cross-sectional study focused on differences in molecular signatures indicative of inflammatory states associated with biological aging of human fibroblasts from donors aged 22 to 92 years.
Results:
Gene expression profiling revealed elevated steady-state transcript levels consistent with a chronic inflammatory state in fibroblast cell-strains obtained from older donors.  We also observed enhanced NF-kB DNA binding activity in a subset of strains, and the NF-kB profile correlated with mRNA expression levels characteristic of inflammatory processes, which include transcripts coding for cytokines, chemokines, components of the complement cascade and MHC molecules. This intrinsic low-grade inflammatory state, as it relates to aging, occurs in cultured cells irrespective of the presence of other cell types or the in vivo context.
Conclusions:
Our results are consistent with the view that constitutive activation of inflammatory pathways is a phenomenon prevalent in aged fibroblasts. It is possibly part of a cellular survival process in response to compromised mitochondrial function. Importantly, the inflammatory gene expression signature described here is cell autonomous, i.e. occurs in the absence of prototypical immune or pro-inflammatory cells, growth factors, or other inflammatory mediators. </description>
			<link>http://www.immunityageing.com/content/5/1/5</link>
			
			 	<dc:creator>Andres Kriete, Kelli L. Mayo, Nirupama Yalamanchili, William Beggs, Patrick Bender, Csaba Kari and Ulrich Rodeck</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2008, 5:5</dc:source>
			<dc:date>2008-07-16</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-5-5</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/5/1/4">
            
            <title>Endothelial nitric oxide synthase gene polymorphisms and cardiovascular damage in hypertensive subjects: an Italian case-control study</title>
			<description>Background:
Nitric oxide (NO) synthesized by endothelial nitric oxide synthase (eNOS) plays an important role in regulation of endothelial function and in the control of blood pressure. However, the results from some studies on the association between three clinically relevant eNOS gene polymorphisms (G894T, T786C and intron 4b/a) and essential hypertension are unclear. We designed a case-control study to evaluate the influence of eNOS polymorphisms on target organ damage in 127 hypertensives and 67 normotensives. Clinical evaluation, biochemical parameters, Urinary Albumin Excretion (UAE) and echocardiogram were performed to characterize target organ damage. eNOS polymorphism were recognized by PCR method.
Results:
The distribution of eNOS genotypes was similar in hypertensives and normotensives but 4aa was present in the 2.5% of hypertensives and completely absent in normotensives. Subjects with 4bb, G894T, and T786C genotypes showed an increased prevalence of target organ damage. Moreover prevalence of G894T and introne 4 variants was significantly higher in hypertensives than in normotensives both with cardiovascular damage. Logistic regression analysis didn't show any association between eNOS polymorphisms, Body Mass Index (BMI), hypertension, gender and cardiovascular damage. Only the age (OR 1.11; IC 95% 1.06&#8211;1.18) was predictive of cardiovascular damage in our population.
Conclusion:
Our results seem to indicate a lack of association with eNOS variants and cardiovascular damage onset.</description>
			<link>http://www.immunityageing.com/content/5/1/4</link>
			
			 	<dc:creator>Daniela Colomba, Giovanni Duro, Salvatore Corrao, Christiano Argano, Tiziana Di Chiara, Domenico Nuzzo, Federica Pizzo, Gaspare Parrinello, Rosario Scaglione and Giuseppe Licata</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2008, 5:4</dc:source>
			<dc:date>2008-05-29</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-5-4</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/5/1/3">
            
            <title>The metal ion theory of ageing: dietary target hazard quotients beyond radicals</title>
			<description>Numerous theories of ageing exist and many are interconnected when viewed through a modern integrative biology perspective. Diet provides a link to a large number of the theories that prevail at the molecular levels. In particular, metal ions form key elements of the radical theory along with having established roles in several age-related neurodegenerative disorders. Lifetime exposure to metals has been linked to ageing by contributions to oxidative stress and neurodegenerative disorders. As many foodstuffs contain high levels and diverse profiles of metals, their cumulative effect on ageing warrants investigation. The cumulative level of concern from environmental exposure can be expressed as a dimensionless index of target hazard quotient (THQ) or for known carcinogens, the target cancer risk (TR). This paper posits that a quantifiable relationship exists between ageing and level of concern resulting from cumulated metal exposure; and that this relationship can be used to develop an ageing-related index of concern from chronic metal ion exposure. As individual differences may facilitate or moderate this cumulated exposure, the potential influence on ageing or on the development of neurodegenerative disorders should be included into the model.</description>
			<link>http://www.immunityageing.com/content/5/1/3</link>
			
			 	<dc:creator>Declan P Naughton and Andrea Petr&#243;czi</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2008, 5:3</dc:source>
			<dc:date>2008-05-20</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-5-3</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/5/1/2">
            
            <title>Safety and immunogenicity of an MF59&#8482;-adjuvanted subunit influenza vaccine in elderly Chinese subjects</title>
			<description>Background:
The safety and immunogenicity of an MF59&#8482;-adjuvanted subunit influenza vaccine (Sub/MF59&#8482;; FLUAD&#174;, Novartis Vaccines) was evaluated among elderly Chinese subjects (&#8805; 60 years of age). After a preliminary Phase I, open-label study (n = 25) to assess safety 1&#8211;14 days post-vaccination, a comparative observer-blind, randomised, controlled clinical trial (n = 600) was performed to assess safety and immunogenicity versus a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal&#174;, Novartis Vaccines). Subjects were randomised (2:1) to receive Sub/MF59&#8482; or Subunit.
Results:
Both vaccines were well tolerated, with no vaccine-related serious adverse events reported during the Phase I trial. During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1&#8211;22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P &lt; 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59&#8482; recipients (P &#8804; 0.005). Both vaccines induced a significant (P &lt; 0.001) increase in geometric mean titres (GMTs) for the three strains tested, versus baseline; GMTs against A/H1N1, A/H3N2 and B were significantly higher in the Sub/MF59&#8482; group (P = 0.034, P &lt; 0.001 and P = 0.005, respectively). GMT ratios against A/H1N1, A/H3N2 and B were also significantly higher in the Sub/MF59&#8482; group (P = 0.038, P &lt; 0.001 and P = 0.006, respectively). Similarly, the percentage of subjects achieving seroprotection or seroconversion on Day 22 was greater for Sub/MF59&#8482; recipients, reaching significance for A/H3N2 (P &lt; 0.001).
Conclusion:
MF59&#8482;-adjuvanted subunit influenza vaccine is well tolerated by elderly Chinese subjects and induces a higher level of immunogenicity than a non-adjuvanted subunit influenza vaccine in this population that is at high risk of influenza-related complications.Clinical trial registryhttp://www.clinicaltrials.gov, NCT00310648</description>
			<link>http://www.immunityageing.com/content/5/1/2</link>
			
			 	<dc:creator>Rongcheng Li, Hanhua Fang, Yanping Li, Youping Liu, Michele Pellegrini and Audino Podda</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2008, 5:2</dc:source>
			<dc:date>2008-02-20</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-5-2</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/5/1/1">
            
            <title>Differential effects of age on circulating and splenic leukocyte populations in C57BL/6 and BALB/c male mice</title>
			<description>Background:
Despite several reports on age-related phenotypic changes of the immune system's cells, studies that use a multipoint age comparison between the specific and innate immune cell populations of prototypical Th1- and Th2-type polarized mouse strains are still lacking.
Results:
Using a multipoint age comparison approach, cells from the two major immune system compartments, peripheral blood and spleen, and flow cytometry analysis, we found several principal differences in T cell and professional antigen presenting cell (APC) populations originating from a prototypical T helper (Th) 1 mouse strain, C57BL/6, and a prototypical Th2 strain, BALB/c. For example, regardless of age, there were strain differences in both peripheral blood mononuclear cells (PBMC) and spleens in the proportion of CD4+ (higher in the BALB/c strain), CD8+ T cells and CD11b+/CD11c+ APC (greater in C57BL/6 mice). Other differences were present only in PBMC (MHC class II + and CD19+ were greater in C57BL/6 mice) or differences were evident in the spleens but not in circulation (CD3+ T cells were greater in C57BL/6 mice). There were populations of cells that increased with age in PBMC and spleens of both strains (MHC class II+), decreased in the periphery and spleens of both strains (CD11b+) or did not change in the PBMC and spleens of both strains (CD8+). We also found strain and age differences in the distribution of na&#239;ve and memory/activated splenic T cells, e.g., BALB/c mice had more memory/activated and less naive CD8+ and CD4+ T cells and the C57BL/6 mice.
Conclusion:
Our data provide important information on the principal differences, within the context of age, in T cell and professional APC populations between the prototypical Th1 mouse strain C57BL/6 and the prototypical Th2 strain BALB/c. Although the age-related changes that occur may be rather subtle, they may be very relevant in conditions of disease and stress. Importantly, our data indicate that age and strain should be considered in concert in the selection of appropriate mouse models for immunological research.</description>
			<link>http://www.immunityageing.com/content/5/1/1</link>
			
			 	<dc:creator>Lesya M Pinchuk and Nikolay M Filipov</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2008, 5:1</dc:source>
			<dc:date>2008-02-11</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-5-1</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/4/1/9">
            
            <title>Challenges for vaccination in the elderly</title>
			<description>The increased susceptibility of the elderly to infection presents a major challenge to public health services. An aging immune system is well documented as the cause of increased infection rates in elderly people. Such immunosenescence is multi-factorial and incompletely understood. Immunosenescent changes include malfunctioning of innate immune system cellular receptors; involution of the thymus, with consequent reduction of the na&#239;ve T cell population; alteration of the T cell population composition; modified phenotypes of individual T cells; and replicative senescence of memory cells expressing na&#239;ve markers. Unfortunately, immunosenescence also renders vaccination less effective in the elderly. It is therefore important that the vaccines used against common but preventable diseases, such as influenza, are specifically enhanced to overcome the reduced immune responsiveness of this vulnerable population.</description>
			<link>http://www.immunityageing.com/content/4/1/9</link>
			
			 	<dc:creator>Richard Aspinall, Giuseppe Del Giudice, Rita B Effros, Beatrix Grubeck-Loebenstein and Suryaprakash Sambhara</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2007, 4:9</dc:source>
			<dc:date>2007-12-11</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-4-9</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-12-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/4/1/8">
            
            <title>The effect of aging and caloric restriction on murine CD8+ T cell chemokine receptor gene expression</title>
			<description>Background:
The mechanism explaining the increased disease susceptibility in aging is not well understood. CD8+ T cells are crucial in anti-viral and anti-tumor responses. Although the chemokine system plays a critical role in CD8+ T cell function, very little is known about the relationship between aging and the T cell chemokine system.
Results:
In this study we have examined the effect of aging on murine CD8+ T cell chemokine receptor gene expression. Freshly isolated splenic CD8+ T cells from old C57BL/6 mice were found to have higher CCR1, CCR2, CCR4, CCR5 and CXCR5, and lower CCR7 gene expression compared to their younger cohort. Anti-CD3/anti-CD28 stimulation elicited a similar robust chemokine receptor response from young and old CD8+ T cells. Western blot analyses confirmed elevated protein level of CCR4 and CCR5 in aged CD8+ T cells. Increases in T cell CCR1 and CCR5 expression also correlate to increased in vitro chemotaxis response to macrophage-inflammatory protein-1 &#945;(MIP-1&#945;). Finally, caloric restriction selectively prevents the loss of CD8+ T cell CCR7 gene expression in aging to the level that is seen in young CD8+ T cells.
Conclusion:
These findings are consistent with the notion that aging exists in a state of low grade pro-inflammatory environment. In addition, our results provide a potential mechanism for the reported aging-associated impaired T cell lymphoid homing and allograft response, and reduced survival in sepsis.</description>
			<link>http://www.immunityageing.com/content/4/1/8</link>
			
			 	<dc:creator>Raymond Yung, RuRan Mo, Annabelle Grolleau-Julius and Mark Hoeltzel</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2007, 4:8</dc:source>
			<dc:date>2007-11-14</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-4-8</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/4/1/7">
            
            <title>Zinc-bound metallothioneins and immune plasticity: lessons from very old mice and humans</title>
			<description>The capacity of the remodelling immune responses during stress (named immune plasticity) is fundamental to reach successful ageing. We herein report two pivotal experimental models in order to demonstrate the relevance of the immune plasticity in ageing and successful ageing. These two experimental models will be compared with the capacity in remodelling the immune response in human centenarians. With regard to experimental models, one model is represented by the circadian rhythms of immune responses, the other one is the immune responses during partial hepatectomy/liver regeneration (pHx). The latter is suggestive because it mimics the immunosenescence and chronic inflammation 48 h after partial hepatectomy in the young through the continuous production of IL-6, which is the main cause of immune plasticity lack in ageing. The constant production of IL-6 leads to abnormal increments of zinc-bound Metallothionein (MT), which is in turn unable in zinc release in ageing. As a consequence, low zinc ion bioavailability appears for thymic and extrathymic immune efficiency, in particular of liver NKT cells bearing TCR &#947;&#948;. The remodelling during the circadian cycle and during pHx of zinc-bound MT confers the immune plasticity of liver NKT &#947;&#948; cells and NK cells in young and very old mice, not in old mice. With regard to human centenarians and their capacity in remodelling the immune response with respect to elderly, these exceptional individuals display low zinc-bound MT associated with: a) satisfactory intracellular zinc ion availability, b) more capacity in zinc release by MT, c) less inflammation due to low gene expression of IL-6 receptor (gp130), d) increased levels of IFN-gamma and number of NKT cell bearing TCR &#947;&#948;. Moreover, some polymorphisms for MT tested in PBMCs from human donors are related to successful ageing. In conclusion, zinc-bound MT homeostasis is fundamental to confer the immune plasticity that is a condition "sine qua non" to achieve healthy ageing and longevity.</description>
			<link>http://www.immunityageing.com/content/4/1/7</link>
			
			 	<dc:creator>Eugenio Mocchegiani, Robertina Giacconi, Elisa Muti, Catia Cipriano, Laura Costarelli, Silvia Tesei, Nazzarena Gasparini and Marco Malavolta</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2007, 4:7</dc:source>
			<dc:date>2007-09-29</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-4-7</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/4/1/6">
            
            <title>Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers</title>
			<description>Background:
Drug addiction is associated with significant disease and death, but its impact on the ageing process has not been considered. The recent demonstration that many of the items available in routine clinical pathology have applicability as biomarkers of the ageing process implies that routine clinical laboratory parameters would be useful as an initial investigation of this possibility.
Methods:
12,093 clinical laboratory results 1995&#8211;2006 were reviewed. To make the age ranges of the medical and addicted groups comparable the age range was restricted to 15&#8211;45 years.
Results:
739 drug addicted (DA) and 5834 general medical (GM) age matched blood samples were compared. Significant elevation of immune parameters was noted in the C-reactive protein, erythrocyte sedimentation rate, total lymphocyte count, serum globulins and the globulin:albumin ratio (P &lt; 0.01). Alanine aminotranferase, creatinine, urea, and insulin like growth factor-1 were also significantly higher (P &lt; 0.01) in the DA group. Albumin, body mass index and dihydroepiandrosterone sulphate were unchanged and cholesterol was lower (all P &lt; 0.05).
Conclusion:
These data demonstrate for the first time that addiction is associated with an altered profile of common biomarkers of ageing raising the possibility that the ageing process may be altered in this group. Infective and immune processes may be centrally involved. They suggest that addiction forms an interesting model to further examine the contribution of immune suppression and hyperstimulation to the ageing process.</description>
			<link>http://www.immunityageing.com/content/4/1/6</link>
			
			 	<dc:creator>Albert Stuart Reece</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2007, 4:6</dc:source>
			<dc:date>2007-09-24</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-4-6</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.immunityageing.com/content/4/1/5">
            
            <title>Zinc and ageing: third Zincage conference</title>
			<description>The importance of Zn for optimal functioning of the immune system and antioxidant stress response is well documented. Zn homeostasis influences development and function of immune cells, activity of stress-related and antioxidant proteins [metallothioneins (MT), chaperones, ApoJ, Poly(ADP-Ribose) polymerase-1 (PARP-1) and Methionione Sulfoxide Reductase (Msr), Superoxide Dismutase (SOD)], and helps to maintain genomic integrity and stability. During ageing, the intake of Zn decreases due to inadequate diet and/or intestinal malabsorption, contributing to frailty, general disability and increased incidence of age-related degenerative diseases (cancer, infections and atherosclerosis). Although many factors contributing to Zn deficiency have been identified, the biochemical markers of Zn deficiency as well as the possibility to achieve relevant health benefits through Zn supplementation in the elderly are still a matter for evaluation. Taking into account that Zn homeostasis is regulated by proteins and enzymes for which polymorphisms have been previously found to be associated with successful/unsuccessful ageing, genetic screening might be of added value in evaluating the individual response to Zn supplementation. Biochemical, immunological, dietary and genetic studies aimed at understanding the impact of Zn in healthy ageing, the effect of Zn supplementation in the elderly and finally formulating a rationale for the promotion of correct Zn supplementation were discussed at the international Zincage conference held in Ancona in January 2007.</description>
			<link>http://www.immunityageing.com/content/4/1/5</link>
			
			 	<dc:creator>Eugenio Mocchegiani</dc:creator>
			
			<dc:source>Immunity &amp; Ageing 2007, 4:5</dc:source>
			<dc:date>2007-09-20</dc:date>
			<dc:identifier>doi:10.1186/1742-4933-4-5</dc:identifier>
			
			
							
					<prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
					
			
							
					<prism:issn>1742-4933</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
